Literature DB >> 17891918

Predictors of renal involvement in patients with systemic lupus erythematosus.

Bancha Satirapoj1, Jeerapat Wongchinsri, Nantana Youngprang, Boonraksa Laonapaporn, Thongdee Chitrada, Sumonkarn Lapkittichareonchai, Jayanton Patumanon.   

Abstract

From a cohort of 109 patients (105 females and 4 males) treated for systemic lupus erythematosus (SLE), 20 patients (18.3%) developed new episodes of lupus nephritis and 89 patients (81.7%) remained free of renal involvement during the follow-up period. The mean duration of follow up was 39.1 +/- 54.4 months. Clinical characteristics associated with developing lupus nephritis were a high systolic blood pressure (> or = 130 mmHg), photosensitivity, cutaneous vasculitis and gastrointestinal (GI) symptoms. Laboratory abnormalities associated with the development of lupus nephritis were hemoglobin < 10 mg/dl, hematocrit < 30%, blood urea nitrogen > 12 mg/dl, serum creatinine > 1.3 mg/dl, ESR > 60, the third component of complement (C3) level < 0.45 and positive antidsDNA antibody. After a multivariable analysis, only high systolic blood pressure, cutaneous vasculitis, hemoglobin < 10 mg/dl and serum creatinine > 1.3 mg/dl remained as statistically significant risk factors for developing lupus nephritis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17891918

Source DB:  PubMed          Journal:  Asian Pac J Allergy Immunol        ISSN: 0125-877X            Impact factor:   2.310


  4 in total

1.  Clinicopathological correlation in asian patients with biopsy-proven lupus nephritis.

Authors:  Bancha Satirapoj; Pamila Tasanavipas; Ouppatham Supasyndh
Journal:  Int J Nephrol       Date:  2015-03-19

2.  Urine neutrophil gelatinase-associated lipocalin to predict renal response after induction therapy in active lupus nephritis.

Authors:  Bancha Satirapoj; Chagriya Kitiyakara; Asada Leelahavanichkul; Yingyos Avihingsanon; Ouppatham Supasyndh
Journal:  BMC Nephrol       Date:  2017-08-04       Impact factor: 2.388

3.  Exploring the risk factors for ischemic cerebrovascular disease in systemic lupus erythematosus: A single-center case-control study.

Authors:  Li Su; Zhigang Qi; Shaochen Guan; Lian Wei; Yi Zhao
Journal:  Front Immunol       Date:  2022-09-27       Impact factor: 8.786

4.  Centrally Acting Angiotensin-Converting Enzyme Inhibitor Suppresses Type I Interferon Responses and Decreases Inflammation in the Periphery and the CNS in Lupus-Prone Mice.

Authors:  Cassandra Nocito; Cody Lubinsky; Michelle Hand; Sabeeya Khan; Tulsi Patel; Alecia Seliga; Malika Winfield; Viviana Zuluaga-Ramirez; Nicole Fernandes; Xiangdang Shi; Ellen M Unterwald; Yuri Persidsky; Uma Sriram
Journal:  Front Immunol       Date:  2020-09-15       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.